: European Long-acting Antipsychotics in Schizophrenia Trial (EULAST

Università degli Studi della Campania
October 02 2017
Position Type
Full Time
Organization Type

Schizophrenia is a chronic psychiatric illness with periods of remission and relapse. Patients vary in the frequency and severity of relapse, time until relapse and time in remission. Discontinuation of antipsychotic medication is by far the most important reason for relapse. A possible method to optimize medication adherence is to treat patients with long-term, depot medication rather than oral medication. However, despite its apparent “common sense” this approach has neither been universally accepted by practicing psychiatrists nor unequivocally demonstrated in clinical trials.

This job comes from a partnership with Science Magazine and Euraxess